Business
NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board
NewcelX Ltd. (NASDAQ: NCEL) ("NewcelX"), a biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, today announced the appointment of Dr. Julien Boisdron, MD, a seasoned diabetes expert with extensive experience in Swiss big pharma leadership to its Scientific Advisory Board ("SAB").
About this update from Newcelx Ltd.
[{"type":"text","content":"ZURICH and NESS ZIONA, Israel, Jan. 5, 2026 /PRNewswire/ -- NewcelX Ltd. (NASDAQ: NCEL) ("NewcelX"), a biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, today announced the appointment of Dr. Julien Boisdron, MD, a seasoned diabetes expert with extensive experience in Swiss big pharma leadership to its Scientific Advisory Board ("SAB").","length":447,"tagName":"p"},{"type":"image","alt":"Dr. Julien Boisdron, Scientific Advisory Board NewCelX: “I am honored to join NewCelX and to collaborate on advancing next-generation therapies for diabetes.”","displaySize":"","headline":null,"caption":"Dr. Julien Boisdron, Scientific Advisory Board NewCelX: “I am honored to join NewCelX and to collaborate on advancing next-generation therapies for diabetes.”","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/43849f3051fec38c52666e1df04e28e7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/z_CkPUim0gIf59G_9O9QUw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/43849f3051fec38c52666e1df04e28e7","width":400,"height":400}},"href":"https://mma.prnewswire.com/media/2854279/NewcelX_Dr_Julien_Boisdron.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Dr. Boisdron brings more than two decades of global leadership in diabetes care. He currently serves as Chief Medical Officer for a major Swiss-based multinational large cap pharma company, where he oversees the strategic development of next-generation diabetes technologies, clinical programs, and real-world evidence initiatives. His background includes connected-care innovation, advanced insulin-management systems, and the integration of therapeutic and digital solutions to enhance patient outcomes.","length":505,"tagName":"p"},{"type":"text","content":"In joining the NewcelX SAB, Dr. Boisdron will provide high-level strategic guidance supporting the development of IsletRx, NewcelX's lead therapeutic program a stem-cell-derived islet cell therapy for insulin-dependent Type 1 Diabetes. Type 1 Diabetes represents the Company's primary clinical focus, and Dr. Boisdron will advise on translational strategy as NewcelX advan...